Seeking Alpha: MapLight Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
SAN FRANCISCO and BOSTON, Oct. 29, 2025 (GLOBE NEWSWIRE) -- MapLight Therapeutics, Inc. (MPLT), a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from ...
MapLight Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
MSN: MapLight Therapeutics to join Russell 3000, Russell 2000 and Russell Microcap indexes
MapLight Therapeutics (NASDAQ:MPLT) has been added to the Russell 2000 Index and the broader Russell 3000 Index, effective at the open of U.S. equity markets on , as part of the 2025 ...
MapLight Therapeutics to join Russell 3000, Russell 2000 and Russell Microcap indexes
Business Insider: MapLight Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
MapLight Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
MapLight Therapeutics Inc. filed for an initial public offering, becoming one of few biotechnology firms to move forward with a listing in a tough year for the sector. The Redwood City, ...
Yahoo Finance: MapLight Therapeutics (MPLT): The Best Healthcare Stock Insiders Are Buying
Seeking Alpha: MapLight Therapeutics Updates Expected Timing of Topline Results for Ongoing Phase 2 Studies to Q3 2026
SAN FRANCISCO and BOSTON, Jan. 09, 2026 (GLOBE NEWSWIRE) -- MapLight Therapeutics, Inc. (MPLT) today announced an update to the expected timing of topline results for its ongoing Phase 2 ZEPHYR and ...